Page 2,553«..1020..2,5522,5532,5542,555..2,5602,570..»

CardioWise Completes Installation of the First Totally Integrated CardioWise Analysis Software at National Institutes …

Posted: Published on February 19th, 2015

Fayetteville, Arkansas (PRWEB) February 19, 2015 CardioWise, Inc. has completed development of the first fully integrated version of its Multiparametric Strain Analysis Software (MPSA) and has installed it at the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI). MPSA software is being used in clinical research protocol number 12-H-0078, sponsored by the NHLBI entitled, Preliminary Assessment of Direct Intra-Myocardial Injection of Autologous Bone Marrow-derived Stromal Cells on Patients Undergoing Revascularization for Coronary Artery Disease (CAD) with Depressed Left Ventricular Function. The Principle Investigator is Dr. Keith A. Horvath, the Director of Cardiothoracic Surgery at the NHLBI and Chief of Cardiothoracic Surgery at Suburban Hospital, where he leads the NIH Heart Center. Details of the study are available here: http://clinicalstudies.info.nih.gov/cgi/wais/bold032001.pl?A_12-H-0078.html@mesenchymal@@@@. The recently completed integrated version of CardioWise analysis software has been installed at the NIH; and, Dr. Justin Miller, and Dr. Ming Li, both research fellows in the Cardiothoracic Surgery Research Program of the NHLBI, have been trained on its operation and use. They were assigned to the project by Dr. Horvath and Dr. Andrew Arai, Chief of the Advanced Cardiovascular Imaging Research Group in the NHLBIs Division of Intramural Research. CardioWise has completed validation testing of … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on CardioWise Completes Installation of the First Totally Integrated CardioWise Analysis Software at National Institutes …

After my stem cell transplant update. – Video

Posted: Published on February 19th, 2015

After my stem cell transplant update. By: Melissa Firmes … Continue reading →

Posted in Stem Cell Transplant | Comments Off on After my stem cell transplant update. – Video

IAPAMs Top 5 Aesthetic Medicine Trends for 2015

Posted: Published on February 19th, 2015

(PRWEB) February 19, 2015 In the last 9 years, we have seen consistent growth with many of the tried and true aesthetic procedures like Botox Cosmetic, but it is nice to see some new additions to this year's Aesthetic Medicine trends, says IAPAM executive-director, Jeff Russell. With the ever-advancing area of cosmetic medicine, it is hard to know whats hot and whats not. Newer procedures have now emerged that offer safe and effective treatments to individuals seeking them. But these procedures are not just aimed at improving the cosmetic appearance of the person. Cosmetic procedures initially started as medical therapies that have now expanded their applications, for example, the Botox injection. Not only is it used in treating fine lines and wrinkles, it is an excellent treatment for a condition of the eye called blepharospasm. In 2014, there was quite a shift in the types of procedures sought after by patients. The number of non-surgical procedures in their entirety was higher by 13.1%! Hair removal procedures increased 2%, while microdermabrasion procedures dropped nearly 4%. Here, we look at what we think the world of non-invasive cosmetic procedures will see in 2015. 1. Botulinum Toxin (Botox / Xeomin ) injections will … Continue reading →

Posted in Aesthetic Medicine | Comments Off on IAPAMs Top 5 Aesthetic Medicine Trends for 2015

SMAS Lower Facelift Before and After 2 Weeks Post-Surgery | Dr Andrew Jacono Reviews – Video

Posted: Published on February 19th, 2015

SMAS Lower Facelift Before and After 2 Weeks Post-Surgery | Dr Andrew Jacono Reviews This woman in her sixties describes her experience with a lower facelift and gives her Dr Andrew Jacono reviews. She describes the facelift surgery and her f... By: Dr. Andrew Jacono … Continue reading →

Posted in Aesthetic Surgery | Comments Off on SMAS Lower Facelift Before and After 2 Weeks Post-Surgery | Dr Andrew Jacono Reviews – Video

Top San Diego Plastic Surgeon Launches Financing Options

Posted: Published on February 19th, 2015

San Diego, CA (PRWEB) February 19, 2015 So many individuals want to embark on cosmetic surgery but find they approach a blockade when it comes to payment. Dr. D. Glynn Bolitho, a quadrupled board certified plastic surgeon and current Chief of Plastic Surgery at Scripps Memorial Hospital La Jolla has recently launched new financing options to help make those aesthetic wishes come true. Dr. Bolitho has restructured his office enabling patients an array of opportunities. Theres no longer a need for having to postpone a surgery or treatment due to a lack of funds. Now, patients can turn to various cosmetic surgery financing choices. Dr. Bolithos patient concierge, Karen Martindale, is at the helm of cosmetic surgery refinancing and navigates patients on what path is best for their budget. The most important thing I share with our patients is that there are so many affordable options so one should not resign themselves to thinking there is only one or none, she said. I look upon cosmetic procedures, be it surgical or even nonsurgical, as a treat. Its so well deserved. Dr. Bolithos office is now accepting CareCredit. A respected lender in our industry is the CareCredit healthcare credit card, she … Continue reading →

Posted in Aesthetic Surgery | Comments Off on Top San Diego Plastic Surgeon Launches Financing Options

Seattle submits supplemental BLA to FDA for Phase III Aethera trial of Adcetris in HL patients

Posted: Published on February 19th, 2015

Published 19 February 2015 Seattle Genetics has submitted a supplemental biologics license application (BLA) to the US Food and Drug Administration (FDA) based on data from Phase III Aethera trial of Adcetris (Brentuximab Vedotin) in post-transplant hodgkin lymphoma (HL) patients at high risk of relapse. Adcetris is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in classical HL and systemic anaplastic large cell lymphoma (sALCL). The Phase III trial of Adcetris was carried out as consolidation therapy immediately following an autologous stem cell transplant (ASCT) in HL patients. The trial, which included 329 HL patients, achieved its primary endpoint and showed a significant increase in progression-free survival (PFS) per independent review facility, with a hazard ratio of 0.57 and a p-value of 0.001. Seattle Genetics president and chief executive officer Clay Siegall said: "With approximately half of all Hodgkin lymphoma patients who undergo an autologous stem cell transplant experiencing disease relapse, there is a significant need to identify regimens that extend progression-free survival. "Results from the Aethera trial demonstrated that treating high risk Hodgkin lymphoma patients with Adcetris in following autologous stem cell transplant resulted in a statistically significant improvement in progression-free survival with a manageable safety profile." … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Seattle submits supplemental BLA to FDA for Phase III Aethera trial of Adcetris in HL patients

FDA approves Celgene's Revlimid in combination with dexamethasone to treat multiple myeloma

Posted: Published on February 19th, 2015

PBR Staff Writer Published 19 February 2015 The US Food and Drug Administration (FDA) has expanded the existing indication for Celgene's Revlimid (lenalidomide) in combination with dexamethasone to include patients newly diagnosed with multiple myeloma (NDMM). In June 2006, Revlimid plus dexamethasone was approved for use in multiple myeloma patients who have received at least one prior therapy. The approval of Revlimid was based on safety and efficacy data from Phase III trials, including the FIRST trial (MM-020/IFM 07-01), The randomized, open-label, three-arm FIRST trial evaluated continuous Revlimid in combination with dexamethasone (Rd Continuous) until disease progression versus melphalan, prednisone and thalidomide (MPT) for 18 months as the primary analysis, and a fixed duration of 18 cycles of Rd (Rd18) as a secondary analysis, in 1,623 newly diagnosed patients who were not candidates for stem cell transplant. Median progression-free survival (PFS), which is the length of time a patient lives from study randomization to disease progression or death, was the primary endpoint of the study. Currently, the company has an application under review with the European Medicines Agency (EMA) for approval to use Revlimid to treat adult patients with previously untreated multiple myeloma who are not eligible for transplant. In … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on FDA approves Celgene's Revlimid in combination with dexamethasone to treat multiple myeloma

At London Predictive Toxicology Summit Asymmetrex Presents New Biotech Solutions For Earlier Identification Of Drugs …

Posted: Published on February 19th, 2015

Boston, MA (PRWEB) February 19, 2015 The actual problem with adult stem cell toxicity detection is not a matter of being unable to identify toxic drug candidates. Instead, the problem is identifying them too late in the drug development process, after large expenditures in failed pre-clinical animal testing and clinical trials have occurred. Adult stem cell toxicity shows up as organ and tissue failure. Because of the crucial role of adult stem cells in maintaining, renewing, and repairing human tissues and organs, drug candidates that attack adult stem cells induce intolerable toxicities. In some cases, catastrophic adult stem cell toxicities may not emerge until drugs have reached the marketplace either because of requiring more chronic dosing or because of being limited to susceptible subgroups of patients. Predictive Toxicology Summits have a mission of exchanging ideas and information that might lead to better tools for predicting the safety of new drug candidates earlier and at reduced cost. Of the estimated $50 billion the U.S. drug industry spends to bring 20-30 new drugs to market each year, about 20% of all the expense (est. $10 billion) is due to animal testing and clinical trials of compounds that fail because of unacceptable toxicity. … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on At London Predictive Toxicology Summit Asymmetrex Presents New Biotech Solutions For Earlier Identification Of Drugs …

"She's Happy" Stem Cell Miracles in USA – Video

Posted: Published on February 19th, 2015

"She's Happy" Stem Cell Miracles in USA Meet Mary Taylor, she was blind for four years from wet and dry Macular Degeneration. Her son Richard, was a previous patient of Regenerative Medical Group, ... By: iManifestart … Continue reading →

Comments Off on "She's Happy" Stem Cell Miracles in USA – Video

Stem Cell Treatment for Mr. Hockey Stirs Controversy

Posted: Published on February 19th, 2015

Any hockey fan would recognize Mr. Hockey Gordie Howe and remember the former Red Wing star as one of the toughest players in the history of the game. His name is famously, if somewhat incorrectly, connected to the unofficial Gordie Howe Hat Trick, in which a player records a goal, an assist, and a fight in the same game. His remarkable career spanned six decades, including a record-setting five in the NHL, and his contributions to the game have lasted long after his retirement. Struck By Illness Sadly, Howe suffered a severe stroke in October of 2014. Friends, family, and fans expected the worst. The 86-year-old legends condition seemed to deteriorate rapidly. When he was released to his daughters home in Texas, many people thought Mr. Hockey would not survive long. Then surprising news of significant recovery began to surface. On February 6, Howe made an almost unbelievable public appearance and looked quite well considering what hed been through. Controversial Treatment It is now being widely reported that, in December, Howe underwent a stem cell treatment in Mexico. The treatment was developed by San Diego-based Stemedica. Since then, Mr. Hockey has been on the mend. But many experts are questioning … Continue reading →

Comments Off on Stem Cell Treatment for Mr. Hockey Stirs Controversy

Page 2,553«..1020..2,5522,5532,5542,555..2,5602,570..»